<DOC>
	<DOCNO>NCT00535873</DOCNO>
	<brief_summary>Primary Objective : - To assess activity lenalidomide patient previously untreated chronic lymphocytic leukemia ( CLL ) age 65 older . Secondary Objective : - To assess tolerability lenalidomide patient untreated CLL age 65 older</brief_summary>
	<brief_title>Lenalidomide Initial Treatment Patients With Chronic Lymphocytic Leukemia ( CLL ) Age 65 Older</brief_title>
	<detailed_description>The Study Drug : Lenalidomide design change body 's immune system may also interfere development tiny blood vessel help support tumor growth . Therefore , theory , may decrease prevent growth cancer cell . Drug Administration : If find eligible take part study , take lenalidomide mouth every morning time day 28 day . Twenty-eight ( 28 ) day consider 1 cycle . The dose schedule lenalidomide may adjust , depend disease responds side effect may experience . Swallow lenalidomide capsule whole water time day . Do break , chew open capsule . If miss dose lenalidomide , take soon remember day . If miss take dose entire day , take regular dose next schedule day ( NOT take double regular dose make miss dose ) . Concomitant Medications : Allopurinol prescribe first 14 day treatment . This medication take mouth help protect kidney function . Study Visits : During study , blood ( 1 tablespoon ) drawn every week best dose lenalidomide find . Blood test ( 1 tablespoon ) may do often dose medication need change experience intolerable side effect . Women able child must negative urine blood ( le 1 teaspoon ) pregnancy test 10 - 14 day 24 hour start lenalidomide therapy , even menstrual period due treatment disease little one menstrual period past 24 month . If regular menstrual cycle , pregnancy test every week first 4 week , every 4 week take lenalidomide , take lenalidomide therapy , 28 day stop take lenalidomide . If irregular menstrual cycle , pregnancy test every week first 4 week , every 2 week take lenalidomide , take lenalidomide therapy , 14 day 28 day stop take lenalidomide . Every month first 3 month , Months 6 , 9 , 12 , 15 physical exam see . After 15-month visit , physical exam every 6 month . After first 3 month , every 6 month ( unless study doctor think necessary ) , bone marrow biopsy aspirate perform check status disease . Length Study : You may stay study long benefitting . You take study early disease get bad intolerable side effect occur . This investigational study . Lenalidomide FDA approve commercially available . Lenalidomide approve treatment patient transfusion-dependent anemia due Low- Intermediate-1-risk myelodysplastic syndrome associate chromosome 5 abnormality without chromosome abnormality . Lenalidomide also approve combination dexamethasone treatment patient multiple myeloma receive least one prior therapy . Its use study , disease , investigational . Up 60 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Patients untreated CLL small lymphocytic lymphoma ( SLL ) indication treatment accord NCI Working Group guidelines.Patients receive single agent rituximab allow participate study . 2 . Age 65 old 3 . Eastern Cooperative Oncology Group ( ECOG ) /World Health Organization ( WHO ) performance status 02 . 4 . Adequate renal function indicate serum creatinine less equal 2 adequate hepatic function indicate total bilirubin less equal upper level normal alanine aminotransferase ( ALT ) less equal 2 upper limit normal ( ULN ) . 5 . Able understand sign Informed Consent investigational nature , study design , risk benefit explain . 6 . Able adhere study visit schedule protocol requirement . 7 . Disease free prior malignancy 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Patients malignancy indolent behavior prostate cancer treat radiation enrol study long reasonable expectation cure treatment modality receive . 8 . Females childbearing potential ( FCBP ) . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . Must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 1014 day prior within 24 hour start lenalidomide must either commit continue abstinence 9 . Continued . heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide . FCBP must also agree ongoing pregnancy test . 10 . Men must agree use condom sexual contact female child bear potential even successful vasectomy . 11 . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 12 . All patient must able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant Acetylsalicylic Acid ( ASA ) may use warfarin low molecular weight heparin . 1 . Known sensitivity thalidomide derivative . 2 . Documented prolymphocytic leukemia ( prolymphocytes 55 % blood ) . 3 . Known positivity HIV active hepatitis ( B C ) . 4 . A serious medical condition , laboratory abnormality psychiatric illness would interfere ability patient participate program accord judgement Principal Investigator . 5 . Active cardiovascular disease define New York Heart Association Class 3 4 . 6 . History erythema nodosum characterize desquamating rash take thalidomide similar drug . 7 . Concurrent use chemotherapy agent . 8 . Pregnant breast feeding female . Lactating female must agree breast feed take lenalidomide . 9 . No known history tuberculosis recent exposure tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>SLL</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>Untreated CLL</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Oral</keyword>
</DOC>